Loading...
Funding rounds, M&A, IPOs, and market analysis—where capital is flowing and why the tape moves.
Private equity investment in healthcare surged to a record $191 billion in 2025, but rising competition is driving up prices and increasing pressure on investors to deliver successful exits.
Private equity investment in healthcare surged to a record $191 billion in 2025, but rising competition is driving up prices and increasing pressure on investors to deliver successful exits.
READ MORE
Sanofi's CEO is strategically capitalizing on the vaccine biotech market dip, investing in Dynavax despite political challenges that have affected short-term sales.
Pomelo Care raised $92 million in a Series C financing round led by Stripes to scale its healthcare offerings beyond maternity care, signaling the company's growth ambitions in broader care segments.
Aktis Oncology opened 2026’s biotech IPO slate with a $318 million raise to develop novel miniprotein-based radioconjugates.
Matt Holt, former New Mountain Capital exec, plans a $30 billion deal to merge five health tech startups into a unified platform called Thoreau, aiming for healthcare service simplification.
Matt Holt pursues a potential $30 billion deal to merge five health tech startups into a single platform aimed at simplification and integration.
Parabilis Medicines led a biotech fundraising surge with a $305 million capital raise aimed at advancing its lead cancer drug into late-stage clinical trials.
Parabilis Medicines has raised $305 million to advance its lead oncology candidate toward late-stage clinical trials, signaling heightened investor interest in cancer therapies.
Obesity and diabetes drug R&D partnerships hit a record $20.2 billion in total deal value last year, fueled by significant M&A activity despite a downturn in IPOs and venture funding.
In 2025, obesity and diabetes R&D partnerships reached a historic $20.2 billion in total deal value, driven by heightened M&A activity despite declines in IPOs and venture funding.
Catalio Capital has named a new chief executive officer for its latest biotech venture focused on autoimmune disorders, signaling active investment momentum in this therapeutic area.
